These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 17720276)

  • 21. Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis.
    Guetz GD; Landre T; Uzzan B; Chouahnia K; Nicolas P; Morere JF
    Target Oncol; 2016 Feb; 11(1):41-7. PubMed ID: 26092590
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Comparison of paclitaxel and carboplatin versus ifosfamide, etoposide, and carboplatin regimen for treatment of patients with advanced non-small cell lung cancer].
    Li DX; Chen XB
    Ai Zheng; 2002 Apr; 21(4):412-5. PubMed ID: 12452023
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data.
    Rossi A; Di Maio M; Chiodini P; Rudd RM; Okamoto H; Skarlos DV; Früh M; Qian W; Tamura T; Samantas E; Shibata T; Perrone F; Gallo C; Gridelli C; Martelli O; Lee SM
    J Clin Oncol; 2012 May; 30(14):1692-8. PubMed ID: 22473169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Efficacy and prognostic factors of 178 advanced non-small lung cancer patients undergoing different second-line chemotherapeutic regimens].
    Kong Q; Wang XY; Jiang RC; Ba Y; Li K
    Zhonghua Zhong Liu Za Zhi; 2016 Apr; 38(4):294-9. PubMed ID: 27087377
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aidi injection plus platinum-based chemotherapy for stage IIIB/IV non-small cell lung cancer: A meta-analysis of 42 RCTs following the PRISMA guidelines.
    Wang J; Li G; Yu L; Mo T; Wu Q; Zhou Z
    J Ethnopharmacol; 2018 Jul; 221():137-150. PubMed ID: 29655852
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of irinotecan/platinum versus etoposide/platinum chemotherapy for extensive-stage small cell lung cancer: A meta-analysis.
    Han D; Wang G; Sun L; Ren X; Shang W; Xu L; Li S
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28707433
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-platinum regimens of gemcitabine plus docetaxel versus platinum-based regimens in first-line treatment of advanced non-small cell lung cancer: a meta-analysis on 9 randomized controlled trials.
    Yu Y; Xu X; Du Z; Shi M
    Cancer Chemother Pharmacol; 2012 May; 69(5):1265-75. PubMed ID: 22297708
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
    Hasegawa Y; Ando M; Maemondo M; Yamamoto S; Isa S; Saka H; Kubo A; Kawaguchi T; Takada M; Rosell R; Kurata T; Ou SH
    Oncologist; 2015 Mar; 20(3):307-15. PubMed ID: 25657199
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis.
    Ardizzoni A; Boni L; Tiseo M; Fossella FV; Schiller JH; Paesmans M; Radosavljevic D; Paccagnella A; Zatloukal P; Mazzanti P; Bisset D; Rosell R;
    J Natl Cancer Inst; 2007 Jun; 99(11):847-57. PubMed ID: 17551145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer.
    Qi WX; Shen Z; Yao Y
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):99-106. PubMed ID: 21607554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Gemcitabine in the first line therapy of advanced and metastatic non-small-cell lung carcinoma (NSCLC): review of the results of phase III studies].
    Langer F; Helsberg K; Schütte WH; Leschinger MI
    Onkologie; 2005 Mar; 28 Suppl 1():1-28. PubMed ID: 15802886
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles.
    Rossi A; Di Maio M
    Expert Rev Anticancer Ther; 2016 Jun; 16(6):653-60. PubMed ID: 27010977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326).
    Belani CP; Fossella F
    Cancer; 2005 Dec; 104(12):2766-74. PubMed ID: 16288485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Platinum-doublet chemotherapy as second-line treatment for relapsed patients with small-cell lung cancer: A systematic review and meta-analysis.
    Horiuchi K; Sato T; Kuno T; Takagi H; Hirsch FR; Powell CA; Fukunaga K
    Lung Cancer; 2021 Jun; 156():59-67. PubMed ID: 33894495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Doublets versus single-agent therapy as first-line therapy for elderly patients with advanced non-small cell lung cancer? A systematic review of randomised controlled trials.
    Xu CA; Chang ZY; Wang XJ; Qi HY
    Int J Clin Pract; 2013 Nov; 67(11):1118-27. PubMed ID: 24165426
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: a meta-analysis.
    Des Guetz G; Uzzan B; Nicolas P; Valeyre D; Sebbane G; Morere JF
    Crit Rev Oncol Hematol; 2012 Dec; 84(3):340-9. PubMed ID: 22534083
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes.
    Le Chevalier T; Scagliotti G; Natale R; Danson S; Rosell R; Stahel R; Thomas P; Rudd RM; Vansteenkiste J; Thatcher N; Manegold C; Pujol JL; van Zandwijk N; Gridelli C; van Meerbeeck JP; Crino L; Brown A; Fitzgerald P; Aristides M; Schiller JH
    Lung Cancer; 2005 Jan; 47(1):69-80. PubMed ID: 15603856
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer.
    Schuette WH; Gröschel A; Sebastian M; Andreas S; Müller T; Schneller F; Guetz S; Eschbach C; Bohnet S; Leschinger MI; Reck M
    Clin Lung Cancer; 2013 May; 14(3):215-23. PubMed ID: 23332288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A meta-analysis of platinum plus docetaxel or vinorelbine in the first-line treatment of advanced non-small cell lung cancer].
    Liu T; Wu H; Zhuang X; Lu D; Cai R; Wang W
    Zhongguo Fei Ai Za Zhi; 2014 Apr; 17(4):327-35. PubMed ID: 24758908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.
    Plosker GL; Hurst M
    Pharmacoeconomics; 2001; 19(11):1111-34. PubMed ID: 11735678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.